Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Oncology -El Paso
mi
from
El Paso, TX
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Oncology -El Paso
mi
from
El Paso, TX
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Methodist Hospital
mi
from
Houston, TX
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Tech University Health Sciences Center
mi
from
Lubbock, TX
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Tech University Health Sciences Center
mi
from
Lubbock, TX
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Oncology - Round Rock Cancer Center
mi
from
Round Rock, TX
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Oncology - Round Rock Cancer Center
mi
from
Round Rock, TX
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Oncology
mi
from
Waco, TX
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Oncology
mi
from
Waco, TX
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Skagit Valley Hospital
mi
from
Mount Vernon, WA
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Skagit Valley Hospital
mi
from
Mount Vernon, WA
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Group Health Cooperative
mi
from
Seattle, WA
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Group Health Cooperative
mi
from
Seattle, WA
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
West Virginia University Charleston
mi
from
Charleston, WV
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
West Virginia University Charleston
mi
from
Charleston, WV
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Fox Valley Hematology & Oncology
mi
from
Appleton, WI
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Fox Valley Hematology & Oncology
mi
from
Appleton, WI
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Saint Mary's Hospital
mi
from
Green Bay, WI
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Saint Mary's Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Health System-Franciscan Healthcare
mi
from
La Crosse, WI
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Health System-Franciscan Healthcare
mi
from
La Crosse, WI
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Marshfield Clinic
mi
from
Marshfield, WI
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Marshfield Clinic
mi
from
Marshfield, WI
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Saint Nicholas Hospital
mi
from
Sheboygan, WI
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Saint Nicholas Hospital
mi
from
Sheboygan, WI
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Vince Lombardi Cancer Clinic
mi
from
Two Rivers, WI
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Vince Lombardi Cancer Clinic
mi
from
Two Rivers, WI
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
San Juan City Hospital
mi
from
San Juan,
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
San Juan City Hospital
mi
from
San Juan,
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Kapiolani Medical Center at Pali Momi
mi
from
'Aiea, HI
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Kapiolani Medical Center at Pali Momi
mi
from
'Aiea, HI
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Oncare Hawaii Inc - Kapiolani Medical Center at Pali Momi
mi
from
'Aiea, HI
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Oncare Hawaii Inc - Kapiolani Medical Center at Pali Momi
mi
from
'Aiea, HI
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Good Samaritan Regional Medical Center
mi
from
Mount Vernon, IL
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Good Samaritan Regional Medical Center
mi
from
Mount Vernon, IL
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Union Hospital of Cecil County
mi
from
Elkton, MD
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Union Hospital of Cecil County
mi
from
Elkton, MD
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Lakeland Hospital
mi
from
Saint Joseph, MI
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Lakeland Hospital
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Wright-Patterson Medical Center
mi
from
Wright-Patterson Air Force Base, OH
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Wright-Patterson Medical Center
mi
from
Wright-Patterson Air Force Base, OH
Click here to add this to my saved trials
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Legacy Mount Hood Medical Center
mi
from
Gresham, OR
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Legacy Mount Hood Medical Center
mi
from
Gresham, OR
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
St. Joseph's Orange
mi
from
Orange, CA
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
St. Joseph's Orange
mi
from
Orange, CA
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
Penrose Cancer Center
mi
from
Colorado Springs, CO
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
Penrose Cancer Center
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
The Hartford Hospital
mi
from
Hartford, CT
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
Christiana Care Health Services, Inc
mi
from
Newark, DE
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
Christiana Care Health Services, Inc
mi
from
Newark, DE
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
Northside Hospital
mi
from
Atlanta, GA
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
Northside Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
St. Joseph's/Candler Health System
mi
from
Savannah, GA
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
St. Joseph's/Candler Health System
mi
from
Savannah, GA
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
Our Lady of the Lake/ Mary Bird Perkins
mi
from
Baton Rouge, LA
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
Our Lady of the Lake/ Mary Bird Perkins
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
The Cancer Institute Catholic Health Initiatives
mi
from
Towson, MD
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
The Cancer Institute Catholic Health Initiatives
mi
from
Towson, MD
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
Billings Clinical Cancer Center
mi
from
Billings, MT
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
Billings Clinical Cancer Center
mi
from
Billings, MT
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
CHI, St. Fancis
mi
from
Grand Island, NE
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
CHI, St. Fancis
mi
from
Grand Island, NE
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
CHI, Good Samaritan
mi
from
Kearney, NE
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
CHI, Good Samaritan
mi
from
Kearney, NE
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
Lehigh Valley Hospital
mi
from
Allentown, PA
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
Lehigh Valley Hospital
mi
from
Allentown, PA
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
Spartanburg Regional Hospital
mi
from
Spartanburg, SC
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
Spartanburg Regional Hospital
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
Sanford Health
mi
from
Sioux Falls, SD
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
Sanford Health
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
Ascension Health Systems
mi
from
Milwaukee, WI
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
Ascension Health Systems
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer
A Two Steps Phase I Trial of Pazopanib or Pemetrexed in Combination With Crizotinib Followed by the Triplet, Crizotinib Plus Pazopanib Plus Pemetrexed in Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer
A Two Steps Phase I Trial of Pazopanib or Pemetrexed in Combination With Crizotinib Followed by the Triplet, Crizotinib Plus Pazopanib Plus Pemetrexed in Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
Inhibiting the Systemic Autophagic Syndrome - A Phase I/II Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC). A Cytokine Working Group (CWG) Study
Status: Enrolling
Updated:  12/31/1969
Loyola University Chicago
mi
from
Maywood, IL
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
Inhibiting the Systemic Autophagic Syndrome - A Phase I/II Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC). A Cytokine Working Group (CWG) Study
Status: Enrolling
Updated: 12/31/1969
Loyola University Chicago
mi
from
Maywood, IL
Click here to add this to my saved trials
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
Inhibiting the Systemic Autophagic Syndrome - A Phase I/II Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC). A Cytokine Working Group (CWG) Study
Status: Enrolling
Updated:  12/31/1969
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
Inhibiting the Systemic Autophagic Syndrome - A Phase I/II Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC). A Cytokine Working Group (CWG) Study
Status: Enrolling
Updated: 12/31/1969
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
Inhibiting the Systemic Autophagic Syndrome - A Phase I/II Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC). A Cytokine Working Group (CWG) Study
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
Inhibiting the Systemic Autophagic Syndrome - A Phase I/II Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC). A Cytokine Working Group (CWG) Study
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
Inhibiting the Systemic Autophagic Syndrome - A Phase I/II Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC). A Cytokine Working Group (CWG) Study
Status: Enrolling
Updated:  12/31/1969
Dartmouth-Hitchcock Medical Center
mi
from
Hanover, NH
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
Inhibiting the Systemic Autophagic Syndrome - A Phase I/II Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC). A Cytokine Working Group (CWG) Study
Status: Enrolling
Updated: 12/31/1969
Dartmouth-Hitchcock Medical Center
mi
from
Hanover, NH
Click here to add this to my saved trials
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
Inhibiting the Systemic Autophagic Syndrome - A Phase I/II Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC). A Cytokine Working Group (CWG) Study
Status: Enrolling
Updated:  12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
Inhibiting the Systemic Autophagic Syndrome - A Phase I/II Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC). A Cytokine Working Group (CWG) Study
Status: Enrolling
Updated: 12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
Inhibiting the Systemic Autophagic Syndrome - A Phase I/II Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC). A Cytokine Working Group (CWG) Study
Status: Enrolling
Updated:  12/31/1969
Providence Health & Services
mi
from
Portland, OR
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
Inhibiting the Systemic Autophagic Syndrome - A Phase I/II Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC). A Cytokine Working Group (CWG) Study
Status: Enrolling
Updated: 12/31/1969
Providence Health & Services
mi
from
Portland, OR
Click here to add this to my saved trials
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
Inhibiting the Systemic Autophagic Syndrome - A Phase I/II Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC). A Cytokine Working Group (CWG) Study
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Cancer Institute / UPMC CancerCenter
mi
from
Pittsburgh, PA
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
Inhibiting the Systemic Autophagic Syndrome - A Phase I/II Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC). A Cytokine Working Group (CWG) Study
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Cancer Institute / UPMC CancerCenter
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA
Phase I/II Study of Intravenous Ascorbic Acid in Combination With Irinotecan Versus Irinotecan Alone for Advanced Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA
Phase I/II Study of Intravenous Ascorbic Acid in Combination With Irinotecan Versus Irinotecan Alone for Advanced Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Photoacoustic Imaging (PAI) of the Prostate: A Clinical Feasibility Study
Photoacoustic Imaging (PAI) of the Prostate: A Clinical Feasibility Study
Status: Enrolling
Updated:  12/31/1969
Stanford University Cancer Institute
mi
from
Stanford, CA
Photoacoustic Imaging (PAI) of the Prostate: A Clinical Feasibility Study
Photoacoustic Imaging (PAI) of the Prostate: A Clinical Feasibility Study
Status: Enrolling
Updated: 12/31/1969
Stanford University Cancer Institute
mi
from
Stanford, CA
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors
Pharmacokinetic-Driven Individualization of Pazopanib Therapy in Patients With Solid Tumors: A Phase I Study
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Florida
mi
from
Jacksonville, FL
Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors
Pharmacokinetic-Driven Individualization of Pazopanib Therapy in Patients With Solid Tumors: A Phase I Study
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors
Pharmacokinetic-Driven Individualization of Pazopanib Therapy in Patients With Solid Tumors: A Phase I Study
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors
Pharmacokinetic-Driven Individualization of Pazopanib Therapy in Patients With Solid Tumors: A Phase I Study
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Alabama
mi
from
Birmingham, AL
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials